MindMed Investor Presentation March 2023 | Psychedelic Medicine Development

MindMed is a neuro-pharmaceutical drug development company focused on developing psychedelic-inspired medicines and non-hallucinogenic derivatives for brain health conditions. The company's lead program features zolunicant, a non-hallucinogenic synthetic derivative designed for clinical development under established regulatory frameworks. This March 2023 presentation outlines MindMed's product pipeline and development strategy in the emerging psychedelic medicine sector.